An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A recent case report describes a person who had very bad stomach and digestive symptoms after restarting their usual dose of semaglutide (the drug in Ozempic/Wegovy) once they stopped fasting for Ramadan. In simple terms: they paused the medicine while fasting, went back on the same dose afterward, and then developed severe nausea, vomiting, abdominal pain or other gut problems that landed them in medical care. Semaglutide is a medicine that acts like a natural gut hormone involved in appetite and digestion. Doctors prescribe it for type 2 diabetes and for weight loss because it helps people feel fuller, eat less, and it slows how fast the stomach empties. It is usually given as a weekly injection at a steady “maintenance” dose once a patient has reached their target. Like many drugs that affect digestion, it commonly causes mild nausea or stomach upset when people start it, which often gets better over time. This report focuses on a single person whose routine was altered by Ramadan, a month during which some people fast from dawn to dusk. They stopped taking semaglutide during the fasting period and later resumed the full maintenance dose rather than restarting at a lower dose. After restarting, they had severe gastrointestinal intolerance — worse than the usual mild side effects — severe enough to be noteworthy to clinicians. Because this is a single case, it doesn’t prove that everyone who pauses semaglutide will have the same reaction, but it does highlight a possible problem when treatment is interrupted and then restarted at the prior dose without tapering. Why this matters: many people pause medications when their eating schedule changes, such as during religious fasting, travel, or illness. If resuming a full dose of semaglutide can cause unexpectedly severe stomach symptoms in at least some people, clinicians and patients need to be cautious. This is especially relevant for people who use semaglutide for diabetes or weight management and who plan to change their routine temporarily. It suggests doctors might want to give advice about how to restart — for example, resuming at a lower dose and increasing slowly — though the report itself does not test that approach. Caveats and risks: this is a single case report, not a controlled study. It raises a possible concern but does not establish how common or predictable this reaction is. Semaglutide’s usual side effects include nausea, vomiting, constipation or diarrhea, and these are typically dose-related and often improve over weeks. People with severe symptoms should seek medical care. Anyone thinking of pausing or restarting semaglutide—especially for fasting—should check with their prescribing clinician first, because individual health conditions, other medications, and the reason for dosing changes matter. Regulatory guidance for semaglutide has not changed based on one case report. Bottom line: pausing semaglutide during fasting then going straight back to the full maintenance dose may, in rare cases, trigger severe digestive problems, so talk with your doctor about how to stop and restart safely.
Source: Cureus